Cardiovascular risk of selective cyclooxygenase-2 inhibitors

Objective: To study the clinical safety of selective cyclooxygenase-2 inhibitors which mainly include rofecoxib,celecoxib,valdecoxib and lumiracoxib.Methods: The related literatures were searched for and analyzed retrospectively with clinical practice.Results: The selective cyclooxygenase-2 inhibitors including rofecoxib,celecoxib,valdecoxib and lumiracoxib could increase the risk of cardiovascular event and the risk of rofecoxib was higher than celecoxib.Conclusion: Cardiovascular risk is of class effect of the selective cyclooxygenase-2 inhibitors.Supervision of them in clinical use should be intensified and the cardiovascular safety of these drugs should be investigated further.